Author | Ronald de Wit, MD, PhD | OncLive

Author | Ronald de Wit, MD, PhD


Dr. de Wit on Rationale for Phase III CARD Trial in Metastatic CRPC

October 24, 2019

Ronald de Wit, MD, PhD, discusses the rationale for the randomized phase III CARD trial which showed a significant overall survival benefit with third-line cabazitaxel in patients with metastatic castration-resistant prostate cancer.

Dr. de Wit Discusses Findings With Pembrolizumab in NMIBC

November 17, 2018

Ronald de Wit, MD, PhD, group leader, Experimental Systematic Therapy of Urogenital Cancers program, Erasmus MC Cancer Institute, Rotterdam, Netherlands, discusses findings with pembrolizumab (Keytruda) in non-muscle invasive bladder cancer.